Evidence map›Paper›PMID 29514912›Full record

ArticleJournal of virology2018

Adenovirus Vector Vaccination Impacts NK Cell Rheostat Function following Lymphocytic Choriomeningitis Virus Infection.

Eryn Blass, Malika Aid, Amanda J Martinot, Rafael A Larocca, Zi Han Kang, Alexander Badamchi-Zadeh, Pablo Penaloza-MacMaster, R Keith Reeves, Dan H Barouch

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Targeting natural killer cells to enhance vaccine responses.Trends in pharmacological sciences · 2021
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Eryn BlassCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Malika AidCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Amanda J MartinotCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Rafael A LaroccaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Zi Han KangCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Alexander Badamchi-ZadehCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Pablo Penaloza-MacMasterDepartment of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
R Keith ReevesCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA dbarouch@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USHarvard University · USNorthwestern University · USRagon Institute of MGH, MIT and Harvard · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology and Immunology Technology CoreP30AI117943 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Michael E Newcomb · 2015 to 2026
$38.4M
Preclinical Evaluation of Novel Ad/MVA and Ad/Protein HIV-1 VaccinesU19AI096040 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SEAMAN, MICHAEL SCOTT · 2012 to 2016
$18.0M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Antigen-Specific NK Cell Memory Against SIV and HIV VaccinesR01AI120828 · NIAID · DUKE UNIVERSITY · PI REEVES, ROGER KEITH · 2017 to 2020
$3.5M
High-Throughput TB Vaccine Antigen DiscoveryK08AI135098 · NIAID · TUFTS UNIVERSITY BOSTON · PI MARTINOT, AMANDA · 2018 to 2022
$931k
Antigen-Specific NK Cell Memory Against SIV and SIV VaccinesR56AI120828 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI REEVES, ROGER KEITH · 2015 to 2015
$717k
Development of Immune-Modulated HIV VaccinesK22AI118421 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PENALOZA, PABLO · 2016 to 2017
$270k
NIAID NIH HHS K08 AI135098NIAID NIH HHS K22 AI118421NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI117943NIAID NIH HHS R01 AI120828NIAID NIH HHS R56 AI120828NIAID NIH HHS T32 AI007245NIAID NIH HHS U19 AI096040
6 · The paper itself

Abstract

Natural killer (NK) cells respond rapidly as a first line of defense against infectious pathogens. In addition, NK cells may provide a "rheostat" function and have been shown to reduce the magnitude of antigen-specific T cell responses following infection to avoid immunopathology. However, it remains unknown whether NK cells similarly modulate vaccine-elicited T cell responses following virus challenge. We used the lymphocytic choriomeningitis virus (LCMV) clone 13 infection model to address whether NK cells regulate T cell responses in adenovirus vector-vaccinated mice following challenge. As expected, NK cell depletion in unvaccinated mice resulted in increased virus-specific CD4

Indexed as

Adenoviruses, HumanAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleKiller Cells, NaturalLymphocyte DepletionLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMiceMice, Inbred C57BLVaccinationViral VaccinesViral Vaccinesadenoviruseslymphocytic choriomeningitis virusNK cellsvaccines

Identifiers

PMID29514912
PMCPMC5952142
OpenAlexW2790216561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.